MK-0683
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for MK-0683, covering 2011-12-12 to 2021-04-09. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) [Phase 1]